UCB and Biogen’s drug dapirolizumab pegol has met the primary endpoint of improvement in disease activity in lupus patients.

UCB and Biogen have announced positive Phase III clinical trial results for PHOENYCS GO study, evaluating dapirolizumab pegol, a new treatment for moderate-to-severe systemic lupus erythematosus (SLE) ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates ...

It is difficult to predict with a sufficient degree of accuracy using the techniques currently available whether a biopharmaceutical will be immunogenic when tested in humans and if so, to what ...

Both circulating and mucosal platelets express activation markers such as P-selectin and CD40L, and are able activate HIMECs in a CD40-dependent manner, resulting in increased surface expression of ...

Tonix's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting ...

这些药物包括：优化肿瘤抗原释放和呈递的药物（放疗，化疗，癌症疫苗，溶瘤病毒），激活共刺激分子以改善抗原呈递细胞（APCs）活性（靶向ICOS，ICOSL，OX40，CD40和CD40L的受体激动剂），以及靶向先天免疫的药物，例如：模式识别受体（PRRs）、细胞因子、自然 ...